Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

Movement Disorders

Volumn 28, Issue 8, 2013, Pages 1138-1141

  Mizuno, Yoshikuni ^a   Kondo, Tomoyoshi ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Rehabilitation Hananoie Hospital   (Japan)

Author keywords

Istradefylline; Levodopa; Motor complications; Parkinson's disease; Wearing off

Indexed keywords

ISTRADEFYLLINE; LEVODOPA; PLACEBO; ADENOSINE A2 RECEPTOR ANTAGONIST; PURINE DERIVATIVE;

ADJUVANT THERAPY; AGED; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL PNEUMONIA; BILE DUCT CANCER; BREAST CANCER; BRONCHITIS; CONTROLLED STUDY; DELIRIUM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; DYSKINESIA; FEMALE; GAIT DISORDER; HALLUCINATION; HEART INFARCTION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NEURALGIA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SCIATICA; SIDE EFFECT; STOMACH ULCER; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; MOTOR COMPLICATIONS; MULTICENTER STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WEARING-OFF; CLINICAL TRIAL;

ISTRADEFYLLINE; LEVODOPA; MOTOR COMPLICATIONS; PARKINSON'S DISEASE; WEARING-OFF;

ADENOSINE A2 RECEPTOR ANTAGONISTS; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PARKINSON DISEASE; PURINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84881555931     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25418     Document Type: Article

References (19)

1. Rajput AH, Fenton ME, Birdi S, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002;17:289-296.
2. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56:S1-S88.
3. 2A antagonists. Neurology 2003;61:S44-S48.
4. 2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 2005;14:729-738.
5. Park A, Stacy M. Istradefylline for the treatment of Parkinson's disease. Expert Opin Pharmacother 2012;13:111-114.
6. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999;147:90-95.
7. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
8. 2A receptor antagonist in MPTP-treated monkeys. Neurology 1999;52:1673-1677.
9. Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-327.
10. Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.
11. 2A receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.
12. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63:295-302.
13. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70:2233-2240.
14. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008;23:2177-2185.
15. Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord 2012;18:178-184.
16. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M; Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010;25:1437-1443.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
18. Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, Kuwana Y. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000;100:53-62.
19. 2A receptors in the brain. Synapse 2008;62:671-681.